A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Public ClinicalTrials.gov record NCT05952037. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Study identification
- NCT ID
- NCT05952037
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- BeOne Medicines
- Industry
- Enrollment
- 114 participants
Conditions and interventions
Conditions
Interventions
- Sonrotoclax Drug
- Zanubrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 22, 2023
- Primary completion
- Sep 21, 2026
- Completion
- Jul 31, 2028
- Last update posted
- Jan 1, 2026
2023 – 2028
United States locations
- U.S. sites
- 17
- U.S. states
- 17
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010-3012 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Medstar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007-2113 | — |
| University of Miami | Miami | Florida | 33136-2107 | — |
| Northwestern Medicine Cancer Center | Warrenville | Illinois | 60555-3269 | — |
| Mission Cancer and Blood | Waukee | Iowa | 50263 | — |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201-1544 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215-5418 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905-0001 | — |
| Hattiesburg Hematology and Oncology Clinic | Hattiesburg | Mississippi | 39401-7233 | — |
| Memorial Sloan Kettering Cancer Center Mskcc | New York | New York | 10065-6800 | — |
| Atrium Health Levine Cancer Institute (Lci) | Charlotte | North Carolina | 28204-2990 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210-1280 | — |
| Ut Southwestern Medical Center | Dallas | Texas | 75390-7208 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112-5550 | — |
| Virginia Commonwealth University Massey Cancer Center | Richmond | Virginia | 23298 | — |
| University of Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05952037, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 1, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05952037 live on ClinicalTrials.gov.